Biodesix raises FY26 revenue view to $108M-$114M from $106M-$112M

Consensus $108.68M. Backs FY26 gross margin view 80%. Still sees adjusted EBITDA continuing improvement on path to profitability. The company said, “For full year 2026, the Company expects total revenue of $108-114 million, with the midpoint representing approximately 25% growth over 2025. Biodesix (BDSX) expects continued progress toward achieving and maintaining Adjusted EBITDA profitability, driven by increasing sales productivity, expanded clinical evidence supporting the Nodify Lung tests, growth in the Development Services pipeline, and demonstrated operating leverage.”